While several anti-HER3 Abs with therapeutic potential are actively under clinical evaluations, the hope is high for a select few, mainly MM-121/seribantumab and patritumab, both of which have shown encouraging clinic benefits in patients with non-small cell lung cancer [88, 92]. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.